SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-058037
Filing Date
2021-04-30
Accepted
2021-04-30 06:08:34
Documents
6
Period of Report
2021-06-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2111568-2_def14a.htm DEF 14A 424072
2 GRAPHIC lg_checkpoint-4c.jpg GRAPHIC 47337
3 GRAPHIC sg_garrett-gray.jpg GRAPHIC 12875
4 GRAPHIC sg_james-oliviero.jpg GRAPHIC 9244
5 GRAPHIC tm2111568d2-pc_01proxybw.jpg GRAPHIC 365217
6 GRAPHIC tm2111568d2-pc_02proxybw.jpg GRAPHIC 475761
  Complete submission text file 0001104659-21-058037.txt   1662333
Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38128 | Film No.: 21873562
SIC: 2834 Pharmaceutical Preparations